nicotine replacement combined with a novel compound (proban) for smoking cessation: a pilot study
Clicks: 144
ID: 215404
2001
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
144 views
22 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #82 of 165 articles by views in religions
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 165 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Smoking cessation rates with available pharmacological therapies remain suboptimal. Anecdotal observations with a combination of sublingual pralidoxime and ipratropium (ProBAN) suggested that these agents in combination with nicotine gum improved quit rates.
| Reference Key |
leigh2001canadiannicotine
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Richard Leigh;Norman M Viner;Gerard Cox;Jeffrey W Balon;Douglas MC Wilson;Denise O’Shaughnessy;Corinne Walker;Gerry Brosky;Malcolm R Sears |
| Journal | religions |
| Year | 2001 |
| DOI |
10.1155/2001/947097
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.